[go: up one dir, main page]

EA202192290A1 - Композиции и способы получения белковых микрочастиц - Google Patents

Композиции и способы получения белковых микрочастиц

Info

Publication number
EA202192290A1
EA202192290A1 EA202192290A EA202192290A EA202192290A1 EA 202192290 A1 EA202192290 A1 EA 202192290A1 EA 202192290 A EA202192290 A EA 202192290A EA 202192290 A EA202192290 A EA 202192290A EA 202192290 A1 EA202192290 A1 EA 202192290A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
obtaining protein
micron
protein microparticles
Prior art date
Application number
EA202192290A
Other languages
English (en)
Inventor
Филип Брадники
Хантер Чен
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57708873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202192290(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202192290A1 publication Critical patent/EA202192290A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предлагаются частицы микронного размера, содержащие терапевтический белок и необязательно вспомогательные вещества, и покрытие из биосовместимого и биоразлагаемого полимера, а также способы получения и применения этих микрочастиц. Терапевтический белок, приготовленный в виде фармацевтического порошка из частиц микронного размера, сохраняет стабильность в течение длительного периода времени и является пригодным для нанесения полимерного покрытия для замедленного высвобождения, а также сохраняет стабильность в физиологических условиях.
EA202192290A 2015-12-16 2016-12-16 Композиции и способы получения белковых микрочастиц EA202192290A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562268259P 2015-12-16 2015-12-16

Publications (1)

Publication Number Publication Date
EA202192290A1 true EA202192290A1 (ru) 2022-02-28

Family

ID=57708873

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202192290A EA202192290A1 (ru) 2015-12-16 2016-12-16 Композиции и способы получения белковых микрочастиц
EA201891164A EA201891164A1 (ru) 2015-12-16 2016-12-16 Композиции и способы получения белковых микрочастиц

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201891164A EA201891164A1 (ru) 2015-12-16 2016-12-16 Композиции и способы получения белковых микрочастиц

Country Status (22)

Country Link
US (1) US20200022917A1 (ru)
EP (2) EP3389636B1 (ru)
JP (2) JP7185526B2 (ru)
KR (1) KR102714544B1 (ru)
CN (2) CN108366968B (ru)
AU (2) AU2016369557B2 (ru)
BR (1) BR112018010743B1 (ru)
CA (1) CA3003654A1 (ru)
CL (2) CL2018001623A1 (ru)
CO (1) CO2018005920A2 (ru)
DK (1) DK3389636T3 (ru)
EA (2) EA202192290A1 (ru)
ES (2) ES2927348T3 (ru)
HU (1) HUE060148T2 (ru)
IL (3) IL286601B2 (ru)
MX (2) MX2018005384A (ru)
MY (1) MY200764A (ru)
PH (2) PH12018500830A1 (ru)
PL (1) PL3389636T3 (ru)
SG (2) SG11201803197UA (ru)
WO (1) WO2017106716A1 (ru)
ZA (2) ZA201802706B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277958B2 (en) 2011-11-18 2023-11-01 Regeneron Pharma Micro-particles of polymeric proteins
US11654112B2 (en) 2016-11-22 2023-05-23 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
EP3658612A4 (en) 2017-07-25 2021-06-02 Elektrofi, Inc. FORMATION OF PARTICLES WITH SUBSTANCES
TWI774827B (zh) * 2017-08-18 2022-08-21 美商雷傑納榮製藥公司 使用影像毛細管等電聚焦以分析樣品基質中蛋白質變異體之方法
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
AU2018368466B2 (en) 2017-11-17 2024-06-20 Amgen Inc. VEGFR-Fc fusion protein formulations
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
JP2022523510A (ja) 2019-01-31 2022-04-25 エレクトロフィ，インコーポレイテッド 粒子形成及び形態構造
EP4027978A1 (en) 2019-09-13 2022-07-20 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
JP7670704B2 (ja) * 2019-11-15 2025-04-30 シルク テクノロジーズ、リミテッド 絹由来タンパク質の安定した配合物
EP4065086B1 (en) * 2019-11-25 2026-01-28 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
US20230094393A1 (en) * 2020-02-07 2023-03-30 Elektrofi, Inc. Peptide particles and methods of formation
CN115484934A (zh) 2020-04-17 2022-12-16 伊勒卓菲公司 通过连续液滴形成和脱水形成颗粒的方法
JP2023551446A (ja) * 2020-11-25 2023-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 非水膜乳化を使用した持続放出製剤

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210529A (en) 1974-12-26 1980-07-01 Midwest Research Institute Blood compatible polymers and applications thereof
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US5104221A (en) 1989-03-03 1992-04-14 Coulter Electronics Of New England, Inc. Particle size analysis utilizing polarization intensity differential scattering
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
SG106672A1 (en) 2002-03-08 2004-10-29 Asml Netherlands Bv Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
JP4627425B2 (ja) 2004-09-29 2011-02-09 本田技研工業株式会社 無段変速機の変速制御装置
CN105085678B (zh) 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
KR101406811B1 (ko) * 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
UA99608C2 (en) 2007-04-17 2012-09-10 Имклоун Ллк PDGFRb-SPECIFIC INHIBITORS
NZ621174A (en) * 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
EP2406260A1 (en) * 2009-03-11 2012-01-18 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
SG186421A1 (en) 2010-07-02 2013-01-30 Medimmune Llc Antibody formulations
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
IL277958B2 (en) * 2011-11-18 2023-11-01 Regeneron Pharma Micro-particles of polymeric proteins
MX389346B (es) 2012-05-18 2025-03-20 Genentech Inc Formulaciones de anticuerpos monoclonales de alta concentración.
AR091967A1 (es) * 2012-08-02 2015-03-11 Sanofi Sa Articulo de fabricacion que comprende aflibercept o 2iv-aflibercept
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها

Also Published As

Publication number Publication date
HK1251461A1 (zh) 2019-02-01
ZA201802706B (en) 2023-12-20
ES2927348T3 (es) 2022-11-04
PH12021550603A1 (en) 2021-11-03
SG11201803197UA (en) 2018-05-30
PH12018500830A1 (en) 2018-10-29
JP7185526B2 (ja) 2022-12-07
WO2017106716A1 (en) 2017-06-22
AU2016369557A1 (en) 2018-06-07
MY200764A (en) 2024-01-14
ZA202304376B (en) 2024-08-28
CL2023002345A1 (es) 2024-03-15
CO2018005920A2 (es) 2018-06-20
EP3389636A1 (en) 2018-10-24
KR20180088836A (ko) 2018-08-07
IL286601B1 (en) 2023-05-01
IL302211A (en) 2023-06-01
SG10202007834VA (en) 2020-09-29
KR102714544B1 (ko) 2024-10-10
IL286601B2 (en) 2023-09-01
MX2024000362A (es) 2024-01-26
CN114404371A (zh) 2022-04-29
IL259204B (en) 2021-10-31
IL286601A (en) 2021-10-31
AU2016369557B2 (en) 2022-10-20
US20200022917A1 (en) 2020-01-23
BR112018010743A8 (pt) 2019-02-26
BR112018010743A2 (en) 2018-11-21
JP2022185057A (ja) 2022-12-13
BR112018010743B1 (pt) 2024-02-15
JP2019504825A (ja) 2019-02-21
EP3389636B1 (en) 2022-07-20
MX2018005384A (es) 2018-08-16
CA3003654A1 (en) 2017-06-22
DK3389636T3 (da) 2022-09-19
CL2018001623A1 (es) 2018-07-20
AU2022291549A1 (en) 2023-02-02
CN108366968A (zh) 2018-08-03
JP7554243B2 (ja) 2024-09-19
EP4059492A1 (en) 2022-09-21
EP4059492B1 (en) 2024-04-17
PL3389636T3 (pl) 2022-11-28
HUE060148T2 (hu) 2023-02-28
CN108366968B (zh) 2022-02-18
EA201891164A1 (ru) 2018-11-30
AU2022291549B2 (en) 2024-08-08
ES2981791T3 (es) 2024-10-10
IL259204A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
EA202192290A1 (ru) Композиции и способы получения белковых микрочастиц
PL3717471T3 (pl) Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób
MX2020001555A (es) Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201692436A1 (ru) Медицинское применение
EA201791095A1 (ru) Способ лечения рака
EA201491973A1 (ru) Новые соединения
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
EA201892415A1 (ru) Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида
EA201692540A1 (ru) 6,7-дигидропиразоло[1,5-a]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2
CY1121123T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
EP3621593C0 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
IL274123A (en) Co-crystals, their pharmaceutical preparations and treatment methods involving them
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201692496A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
EA201791346A1 (ru) ТВЕРДЫЕ ФОРМЫ, ВКЛЮЧАЮЩИЕ (1E,4E)-2-АМИНО-N,N-ДИПРОПИЛ-8-(4-(ПИРРОЛИДИН-1-КАРБОНИЛ)ФЕНИЛ)-3H-БЕНЗО[b]-АЗЕПИН-4-КАРБОКСАМИД, ИХ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
MX376741B (es) Composición farmaceútica de sulfonamida
EP3402778A4 (en) METHOD AND MEDICINAL COMPOSITIONS FOR TREATING LYME DISEASE
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
ZA202005083B (en) Solid forms of fasoracetam
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
EA201992844A1 (ru) Новые пероральные составы на основе белиностата